|
| |
Biacore launches
new generation system for protein interaction analysis
Unmatched performance of Biacore T100 supports
critical decision-making from research through to manufacturing and QC
Uppsala, Sweden, February 7, 2005. Biacore International AB (Biacore) (SSE: BCOR)
today announced the launch of Biacore T100, a new generation system for protein
interaction analysis.
Biacore T100 provides comprehensive information about how proteins interact with
other molecules. The unique information generated by Biacore T100 is invaluable
for many applications such as elucidation of disease pathways, definition of
therapeutic targets, selection of drug candidates and decisions on the safety of
a protein therapeutic.
Biacore T100 sets the performance standard for protein interaction analysis,
from research through drug discovery and development to manufacturing and QC,
providing the highest quality data to support decisions that ensure productive
research and development. From a single instrument, scientists can determine
affinity and rate constants, binding specificity, concentration and
thermodynamic parameters. In this way, applications as time-consuming as
antibody characterization, which could take weeks by conventional methods, can
be completed in days with Biacore T100. Software wizards assist with the
analysis of every interaction parameter, making the system straightforward to
use and suitable for both novice and experienced users.
Initially acknowledged as essential in basic research, the unique data provided
by Biacore systems are now widely used by biotechnology and pharmaceutical
companies to make well-informed decisions at critical stages throughout the
development and manufacture of novel therapeutics. To fulfill stringent
regulatory requirements, Biacore T100 has been designed with a high level of
in-built GLP/GMP/GCP support and 21 CFR Part 11 compliance. An optional GxP
support package will save users significant time during validation.
Erik Walldén, Biacore’s President and CEO commented:
“Biacore T100 is our new flagship system, the fruit of our skills and expertise
gained through 15 years of experience since we introduced real time protein
interaction analysis into the life science market. We are confident that both
existing and new Biacore users will benefit from the system’s unmatched
performance and ease-of-use. Biacore T100 offers even greater opportunities for
scientists to benefit from real time protein interaction analysis wherever they
work in the life sciences.“
– Ends –
About Biacore
Biacore is a global supplier of systems for protein interaction analysis, an
area of increasing importance for scientists in the academic, pharmaceutical,
biotechnology and diagnostic markets. The Company's systems generate unique data
on the interactions between proteins and other molecules, including small
molecules such as drug candidates. During research, development and manufacture,
these data give insights into protein functionality, elucidate disease
mechanisms and play a key role in the critical decisions needed for efficient
development and production of therapeutics.
Biacore’s products are used in key areas such as antibody characterization,
proteomics, lead characterization, immunogenicity, biotherapeutic development
and production. The Company offers a range of products to meet specific
application needs. Customers include leading life science research centers, all
of the leading global pharmaceutical companies, and a large number of companies
in the emerging biotechnology sector.
Biacore also markets food analysis solutions, providing key manufacturers with a
system and ready-to-use kits for the determination of food quality and safety.
The company has its own direct sales capability in the world's key markets
(United States, Europe, Japan, Australia) and a distribution network in
Asia-Pacific. Biacore was founded in 1984 and is listed on the Stockholm Stock
Exchange (SSE:BCOR).
Further information on Biacore can be found at:
www.biacore.com
Cautionary Statement
This press release contains certain forward-looking statements within the
meaning of the United States Private Securities Litigation Reform Act of 1995,
which, by their nature, involve risk and uncertainty because they relate to
events and depend on circumstances that will occur in the future. There are a
number of factors that could cause actual results and developments to differ
materially from those expressed or implied by these forward-looking statements.
Biacore is a trademark of Biacore AB.
For further information, please contact:
Erik Walldén, President and CEO
+41 (0) 79 769 4542
Scientific/Trade Press Enquiries:
At Biacore:
Sue Cresswell, Market Communication Director
+41 (0) 79 710 8311
At Northbank Communications:
Douglas Pretsell, Senior Account Manager
+44 (0) 20 7886 8158
| |
|
